冠昊生物
(300238)
| 流通市值：25.24亿 | | | 总市值：25.24亿 |
| 流通股本：2.65亿 | | | 总股本：2.65亿 |
| 报告期 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 流动资产: | | | | |
| 货币资金 | 96,726,668.46 | 105,136,100.6 | 131,685,776.16 | 136,297,486.93 |
| 应收票据及应收账款 | 74,827,102.21 | 61,142,630.83 | 77,731,544.7 | 81,508,263.25 |
| 应收账款 | 74,827,102.21 | 61,142,630.83 | 77,731,544.7 | 81,508,263.25 |
| 预付款项 | 10,086,994.43 | 7,215,658.54 | 22,773,813.53 | 10,216,918.99 |
| 其他应收款合计 | 14,111,003.79 | 13,363,635.03 | 7,513,038.35 | 12,986,139.22 |
| 存货 | 68,970,276.51 | 71,601,478.41 | 67,871,381.53 | 69,829,235.6 |
| 其他流动资产 | 10,119,452.76 | 8,818,365.31 | 1,824,434.9 | 5,301,040.89 |
| 流动资产平衡项目 | 0 | 0 | 0 | 0 |
| 流动资产合计 | 274,841,498.16 | 267,277,868.72 | 309,399,989.17 | 316,139,084.88 |
| 非流动资产: | | | | |
| 长期股权投资 | 16,796,101.2 | 16,925,116.83 | 17,020,185.1 | 17,148,598.33 |
| 其他权益工具投资 | 15,154,545.45 | 15,154,545.45 | 15,154,545.45 | 15,154,545.45 |
| 投资性房地产 | 8,903,082.37 | 9,014,366.41 | - | - |
| 固定资产 | 159,545,621.43 | 161,957,544.86 | 174,055,835.44 | 176,771,252.41 |
| 在建工程 | 84,918,583 | 73,991,443.33 | 23,449,037.52 | 11,278,064.04 |
| 使用权资产 | 15,081,111.84 | 16,089,869.59 | 22,198,798.39 | 26,240,303.79 |
| 无形资产 | 76,271,075.67 | 78,660,393.54 | 80,481,228.71 | 82,879,631.93 |
| 开发支出 | 21,603,062 | 20,473,785.26 | 18,834,682.98 | 16,562,933.76 |
| 长期待摊费用 | 4,015,746.82 | 3,693,020.38 | 4,278,046.5 | 6,713,682.02 |
| 递延所得税资产 | 14,878,028.49 | 14,966,060.55 | 13,797,476.65 | 13,873,317.1 |
| 其他非流动资产 | 359,500 | 390,884.48 | 1,761,260 | - |
| 非流动资产平衡项目 | 0 | 0 | 0 | 0 |
| 非流动资产合计 | 417,526,458.27 | 411,317,030.68 | 371,031,096.74 | 366,622,328.83 |
| 资产平衡项目 | 0 | 0 | 0 | 0 |
| 资产总计 | 692,367,956.43 | 678,594,899.4 | 680,431,085.91 | 682,761,413.71 |
| 流动负债: | | | | |
| 短期借款 | 23,518,669.32 | 24,519,463.77 | 25,516,574.88 | 36,031,305.44 |
| 应付票据及应付账款 | 8,004,001.15 | 29,323,170.62 | 3,600,626.93 | 2,607,295.75 |
| 应付账款 | 8,004,001.15 | 29,323,170.62 | 3,600,626.93 | 2,607,295.75 |
| 预收款项 | - | - | 16,656.3 | 20,956.3 |
| 合同负债 | 31,796,390.65 | 21,972,595.4 | 27,992,159.47 | 29,790,539.21 |
| 应付职工薪酬 | 8,748,804.4 | 17,836,628.5 | 16,236,923.7 | 13,009,728.43 |
| 应交税费 | 12,308,020.42 | 8,124,112.79 | 11,610,732.94 | 9,890,241 |
| 其他应付款合计 | 56,325,059.76 | 63,555,990.45 | 71,432,707.21 | 70,197,202.86 |
| 一年内到期的非流动负债 | 7,428,721.08 | 6,073,196.53 | 4,677,249.62 | 9,467,526.8 |
| 其他流动负债 | 1,300,111.12 | 1,311,058.67 | 834,309.15 | 1,996,324.9 |
| 流动负债平衡项目 | 0 | 0 | 0 | 0 |
| 流动负债合计 | 149,429,777.9 | 172,716,216.73 | 161,917,940.2 | 173,011,120.69 |
| 非流动负债: | | | | |
| 长期借款 | 36,045,100.01 | 12,015,033.34 | - | - |
| 租赁负债 | 10,010,589.24 | 12,059,620.68 | 20,439,287.43 | 19,652,812.29 |
| 递延收益 | 20,342,337.09 | 20,646,814.62 | 20,951,292.15 | 22,328,749.73 |
| 递延所得税负债 | 4,886,052.53 | 4,896,968.28 | 5,438,964.61 | 5,466,864.69 |
| 非流动负债平衡项目 | 0 | 0 | 0 | 0 |
| 非流动负债合计 | 71,284,078.87 | 49,618,436.92 | 46,829,544.19 | 47,448,426.71 |
| 负债平衡项目 | 0 | 0 | 0 | 0 |
| 负债合计 | 220,713,856.77 | 222,334,653.65 | 208,747,484.39 | 220,459,547.4 |
| 所有者权益(或股东权益): | | | | |
| 实收资本(或股本) | 265,155,701 | 265,155,701 | 265,155,701 | 265,155,701 |
| 资本公积 | 600,268,565.98 | 600,268,565.98 | 600,268,565.98 | 600,268,565.98 |
| 其他综合收益 | -46,543,836.87 | -46,462,910.94 | -48,036,597.35 | -49,491,221.77 |
| 盈余公积 | 47,110,231.52 | 47,110,231.52 | 43,851,701.31 | 43,851,701.31 |
| 未分配利润 | -331,086,233.7 | -345,477,748.45 | -331,987,310.36 | -342,515,260.46 |
| 归属于母公司股东权益平衡项目 | 0 | 0 | 0 | 0 |
| 归属于母公司股东权益合计 | 534,904,427.93 | 520,593,839.11 | 529,252,060.58 | 517,269,486.06 |
| 少数股东权益 | -63,250,328.27 | -64,333,593.36 | -57,568,459.06 | -54,967,619.75 |
| 股东权益平衡项目 | 0 | 0 | 0 | 0 |
| 股东权益合计 | 471,654,099.66 | 456,260,245.75 | 471,683,601.52 | 462,301,866.31 |
| 负债和股东权益合计 | 692,367,956.43 | 678,594,899.4 | 680,431,085.91 | 682,761,413.71 |
| 公告日期 | 2024-04-26 | 2024-03-06 | 2023-10-25 | 2023-08-23 |
| 审计意见(境内) | | 标准无保留意见 | | |